$-0.17 EPS Expected for Oragenics, Inc. (OGEN) on February, 15

Oragenics, Inc. (NYSEAMERICAN:OGEN) Corporate Logo

Oragenics, Inc. (NYSEAMERICAN:OGEN)’s quarterly earnings will be revealed on February, 15., as reported by Faxor. Wall Street sees -51.43 % EPS growth as of February, 15. Ticker’s shares touched $1 during the last trading session after 4.76% change.Oragenics, Inc. is downtrending after having declined 69.16% since January 12, 2018. OGEN has 3.27M volume or 12.88% up from normal. OGEN underperformed by 69.16% the S&P500.

Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis.The firm is valued at $29.43 million. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates.Currently it has negative earnings. The firm is also developing AG013, which is in initiation of Phase II clinical trial for the treatment of oral mucositis in cancer patients.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.